Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Janus Henderson Group plc reports a passive, non-controlling stake in Revolution Medicines common stock, with disclosed shared voting and dispositive power in the range of 10.45–10.59 million shares, representing about 5.6%–5.7% of the class. The filing identifies both a group-level beneficial figure of 10,590,727 shares (5.7%) and a related subsidiary position of 10,445,374 shares (5.6%), indicating Janus Henderson exercises shared voting and disposition rights over these holdings.
The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also includes a power-of-attorney authorizing compliance signatories to execute and amend related ownership reports on the company's behalf.
Revolution Medicines (RVMD) filed a Form 4 for director Alexis Borisy covering transactions on 26 June 2025.
- 3,142 Restricted Stock Units (RSUs) were acquired at no cost, lifting his direct common-stock position to 2,338,884 shares.
- A new stock-option grant for 11,574 shares was issued at an exercise price of $37.48, expiring on 26 Jun 2035; the award vests in full on the earlier of the first anniversary or the next annual meeting, assuming continued service.
No shares were sold, so Mr. Borisy’s net exposure to RVMD equity increased. Although the incremental RSU amount is small relative to his existing 2.3 million-share stake, the at-the-money option grant and additional RSUs reinforce alignment between the director and shareholders by incentivizing future price appreciation.